EnLys™ Platform

Novel antibacterial for MDR

 1. Novel class of antibacterial agents that directly disrupt bacterial cell walls, enabling rapid efficacy and 

shortening treatment duration for severe infections. 

2. Narrow-spectrum, species-specific targeting: selectively eradicates pathogens while preserving beneficial commensal microbiota. 

3. Low propensity for resistance development: targets highly conserved peptidoglycan layers independent of bacterial metabolic pathways.



Back